Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• OwensMAHortenBCDa SilvaMMHER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissuesClin Breast Cancer200451636915140287
   PubMedGoogle Scholar
• LemmonMASchlessingerJCell signaling by receptor tyrosine kinasesCell201014171117113420602996
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• Graus-PortaDBeerliRRDalyJMHynesNEErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingEMBO J1997167164716559130710
   PubMed Web of Science ®Google Scholar
• ChoHSMasonKRamyarKXStructure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature2003421692475676012610629
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• AlbanellJCodonyJRoviraAMelladoBGasconPMechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4Adv Exp Med Biol200353225326812908564
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• NagyPFriedlanderETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res200565247348215695389
   PubMed Web of Science ®Google Scholar
• DiermeierSHorvathGKnuechel-ClarkeRHofstaedterFSzollosiJBrockhoffGEpidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationExp Cell Res2005304260461915748904
   PubMed Web of Science ®Google Scholar
• LiptonAGoodmanLLeitzelKHER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerBreast Cancer Res Treat20131411435323959396
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• MajewskiIJNuciforoPMittempergherLPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerJ Clin Oncol201533121334133925559818
   PubMed Web of Science ®Google Scholar
• NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol20063526928016683005
   PubMedGoogle Scholar
• ScaltritiMRojoFOcanaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• Parra-PalauJLMoranchoBPegVEffect of p95HER2/611CTF on the response to trastuzumab and chemotherapyJ Natl Cancer Inst201410611
   Google Scholar
• BaselgaJNortonLAlbanellJKimYMMendelsohnJRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsCancer Res19985813282528319661897
   PubMed Web of Science ®Google Scholar
• NeidhartJALaufmanLRVaughnCMcCrackenJDMinimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group studyCancer Treat Rep1980644–56756777427953
   PubMedGoogle Scholar
• CabanillasFBodeyGPBurgessMAFreireichEJResults of a phase II study of maytansine in patients with breast carcinoma and melanomaCancer Treat Rep1979633507509371803
   PubMedGoogle Scholar
• PressMFCordon-CardoCSlamonDJExpression of the HER-2/neu proto-oncogene in normal human adult and fetal tissuesOncogene1990579539621973830
   PubMed Web of Science ®Google Scholar
• SpectorNLXiaWBurrisH3rdStudy of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesJ Clin Oncol200523112502251215684311
   PubMed Web of Science ®Google Scholar
• BarokMJoensuuHIsolaJTrastuzumab emtansine: mechanisms of action and drug resistanceBreast Cancer Res201416220924887180
   PubMed Web of Science ®Google Scholar
• EricksonHKParkPUWiddisonWCAntibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processingCancer Res20066684426443316618769
   PubMed Web of Science ®Google Scholar
• AustinCDDe MaziereAMPisacanePIEndocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinMol Biol Cell200415125268528215385631
   PubMed Web of Science ®Google Scholar
• BarokMTannerMKoninkiKIsolaJTrastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivoBreast Cancer Res2011132R4621510863
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
   PubMed Web of Science ®Google Scholar
• BeeramMKropIEBurrisHAA phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerCancer2012118235733574022648179
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdRugoHSVukeljaSJPhase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyJ Clin Oncol201129439840521172893
   PubMed Web of Science ®Google Scholar
• KropIELoRussoPMillerKDA phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol201230263234324122649126
   PubMed Web of Science ®Google Scholar
• HurvitzSADirixLKocsisJPhase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol20133191157116323382472
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• WelslauMDierasVSohnJHPatient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancerCancer2014120564265124222194
   PubMed Web of Science ®Google Scholar
• KropIEKimSBGonzalez-MartinATrastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialLancet Oncol201415768969924793816
   PubMed Web of Science ®Google Scholar
• WildiersHTrastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: final overall survival results from the phase 3 TH3RESA studySan Antonio Breast Cancer Symposium, SABCS122015 Abstract S5-05
   Google Scholar
• Paper presented at: San Antonio Breast Cancer Symposium, SABCS2015San Antonio, TX
   Google Scholar
• EllisPABarriosCHEiermannWPhase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab+taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE studyPaper presented at: ASCO Annual Meeting ProceedingsChicago2015
   Google Scholar
• SwainSMBaselgaJKimSBPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Engl J Med2015372872473425693012
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGMechanisms of acquired resistance to trastuzumab emtansine (T-DM1)World ADC Summit2011San Francisco, CA
   Google Scholar
• OlsonEMLinNUDiPiroPJResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancerAnn Oncol2012231939721531783
   PubMed Web of Science ®Google Scholar
• GagliatoDMJardimDLMarchesiMSHortobagyiGNMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerOncotarget Epub2016127
   Google Scholar
• BaselgaJLewis PhillipsGDVermaSRelationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancerClin Cancer Res Epub2016226
   Web of Science ®Google Scholar